| Insurance Industry | Financials Sector | Mr. George Achilleos CEO | XSTU Exchange | - ISIN |
| Canada Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
NetraMark Holdings Inc. specializes in developing advanced artificial intelligence (AI) and machine learning (ML) solutions aimed at addressing unique challenges within the pharmaceutical industry in Canada. Formerly known as Nurosene Health Inc., the company underwent a rebranding to NetraMark Holdings Inc. in February 2023. Established in 2016, NetraMark has positioned itself as a trailblazer in leveraging technology to enhance healthcare outcomes. The company's headquarters are located in Toronto, Canada, where its team of experts focuses on innovating and improving the ways pharmaceutical data is analyzed and utilized for drug development and patient care.
An interactive augmented intelligence platform that integrates AI with human insights to optimize pharmaceutical research and development processes. NetraAI is designed to accelerate drug discovery and development, enhancing the efficiency of research studies and clinical trials through advanced data analytics.
This tool represents a breakthrough in data analysis, breaking down complex health datasets into understandable and actionable insights. Netra Shatter utilizes AI-driven algorithms to identify key patterns and correlations that can inform decision-making processes in drug development and personalized medicine.
A comprehensive digital repository of health data, the Netra Health Atlas facilitates an in-depth understanding of various health conditions and treatment outcomes. It serves as a valuable resource for researchers, clinicians, and pharmaceutical companies, offering access to a wealth of information that supports the advancement of medical knowledge and the development of more effective healthcare solutions.